Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabergoline plus oral contraceptives versus oral contraceptives alone for benign ovarian tumors
IRCT20180815040802N1Phase 3Completed
- Sponsor
- Tabriz University of Medical Sciences
- Start
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, triple-blind trial of cabergoline in Benign Ovarian Neoplasm (2 arms), sponsored by Tabriz University of Medical Sciences. Primary endpoint: Size of benign ovarian tumors. Started Aug 2018; status: completed.
02
Drugs
cabergoline
03
Conditions
Benign Ovarian Neoplasm
Beyond the preview
Go deeper on IRCT20180815040802N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20180815040802N1.